Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

NCT ID: NCT07222800Sponsor: PfizerLast updated: 2026-06-04

Summary

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects. The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment. * The study is expected to last approximately 33 months for each participant. * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Arms & interventions

  • DrugPF-08634404

    Solution for infusion

  • BiologicalBevacizumab

    Injection for intravenous use

  • DrugChemotherapy

    Injection for intravenous use

Outcome measures

Primary

  • Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)

    Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective progressive disease (PD) assessed by BICR per RECIST 1.1, or death due to any cause, whichever occurs first.

    Time frame: Approximately 4 years

  • Overall survival (OS)

    Overall survival defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Approximately 4 years

Secondary

  • PFS per RECIST 1.1 by investigator assessment

    Time frame: Approximately 4 years

  • Objective Response Rate (ORR) by BICR

    Time frame: Approximately 4 years

  • Objective Response Rate (ORR) by investigator

    Time frame: Approximately 4 years

  • Duration of Response (DOR) by BICR

    Time frame: Approximately 4 years

  • DOR by investigator

    Time frame: Approximately 4 years

  • PFS2 (PFS after next-line therapy) by investigator

    Time frame: Approximately 4 years

  • Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Through 90 days after the last study intervention; Approximately 4 years

  • Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Through 90 days after the last study intervention; Approximately 4 years

  • Pharmacokinetics (PK): Serum concentration of PF-08634404

    Time frame: Approximately 21 months

  • Immunogenicity: Incidence of positive Anti-Drug Antibody (ADA)

    Time frame: Approximately 21 months

  • Mean scores and Change from baseline in the global health status/quality of life (QoL) score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    Time frame: Approximately 4 years

  • Mean score change from baseline in participant reported function and symptoms scales per EORTC QLQ-CR29

    Time frame: Approximately 4 years

  • Time to definitive deterioration (TTdD) in the global health status/QoL score on the EORTC QLQ-C30

    Time frame: Approximately 4 years

  • Time to definitive deterioration (TTdD) in participant reported function and symptoms per EORTC QLQ-CR29

    Time frame: Approximately 4 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Histological or cytological confirmed colorectal adenocarcinoma. * Evidence of Stage IV metastatic disease. * No prior systemic therapy for metastatic disease. * Eastern Cooperative Oncology Group performance status (ECOG) 0-1 * At least one measurable lesion according to RECIST 1.1 per Investigator assessment. * Adequate hepatic, liver, and renal function Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Locally confirmed BRAF V600E mutation * Locally confirmed microsatellite instability (MSI)-high or DNA mismatch repair deficiency (dMMR) colorectal cancer * Participants with known active symptomatic CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression * Clinically significant risk of hemorrhage or fistula * Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study * History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events * Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose * Participants with active autoimmune diseases requiring systemic treatment within the past 2 years * Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis

Study locations (150)

Ironwood Cancer & Research Centers

Chandler, Arizona, 85224

Recruiting

Ironwood Cancer & Research Centers

Gilbert, Arizona, 85297

Recruiting

Ironwood Cancer & Research Centers

Glendale, Arizona, 85306

Recruiting

Ironwood Cancer & Research Centers

Goodyear, Arizona, 85395

Recruiting

Ironwood Cancer & Research Centers

Mesa, Arizona, 85202

Recruiting

Ironwood Cancer & Research Centers

Mesa, Arizona, 85206

Recruiting

Ironwood Cancer & Research Centers

Phoenix, Arizona, 85028

Recruiting

Ironwood Cancer & Research Centers

Scottsdale, Arizona, 85260

Recruiting

Highlands Oncology Group

Fayetteville, Arkansas, 72703

Recruiting

Highlands Oncology Group

Rogers, Arkansas, 72758

Recruiting

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting

UCSF at Berkeley Outpatient Center

Berkeley, California, 94702

Recruiting

UCSF at China Basin

San Francisco, California, 94107

Recruiting

UCSF at Mount Zion

San Francisco, California, 94115

Recruiting

UCSF at Parnassus

San Francisco, California, 94143

Recruiting

UCSF Medical Center

San Francisco, California, 94158

Recruiting

Rocky Mountain Cancer Centers, LLP

Aurora, Colorado, 80012

Recruiting

Rocky Mountain Cancer Centers - Boulder

Boulder, Colorado, 80303

Recruiting

Rocky Mountain Cancer Centers, LLP

Centennial, Colorado, 80112

Recruiting

Rocky Mountain Cancer Centers, LLP

Colorado Springs, Colorado, 80907

Recruiting

Rocky Mountain Cancer Centers, LLP

Colorado Springs, Colorado, 80923

Recruiting

Intermountain Health Cancer Center Saint Joseph

Denver, Colorado, 80218

Recruiting

Intermountain Health Saint Joseph Hospital - Research Office

Denver, Colorado, 80218

Recruiting

Intermountain Health Saint Joseph Hospital

Denver, Colorado, 80218

Recruiting

Rocky Mountain Cancer Centers, LLP

Denver, Colorado, 80218

Recruiting

Rocky Mountain Cancer Centers, LLP

Denver, Colorado, 80220

Recruiting

Rocky Mountain Cancer Centers, LLP

Englewood, Colorado, 80113

Recruiting

Rocky Mountain Cancer Centers, LLP

Lakewood, Colorado, 80228

Recruiting

Rocky Mountain Cancer Centers, LLP

Littleton, Colorado, 80120

Recruiting

Rocky Mountain Cancer Centers, LLP

Lone Tree, Colorado, 80124

Recruiting

Rocky Mountain Cancer Centers, LLP

Longmont, Colorado, 80504

Recruiting

Rocky Mountain Cancer Centers, LLP

Pueblo, Colorado, 81003

Recruiting

Rocky Mountain Cancer Centers, LLP

Thornton, Colorado, 80260

Recruiting

Florida Cancer Specialists

Bonita Springs, Florida, 34135

Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34211

Recruiting

Comprehensive Hematology Oncology

Brandon, Florida, 33511

Recruiting

Florida Cancer Specialists

Cape Coral, Florida, 33909

Recruiting

BRCR Global - Coral Springs

Coral Springs, Florida, 33065

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33905

Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33908

Recruiting

Comprehensive Hematology Oncology

Largo, Florida, 33770

Recruiting

Cancer Care Centers of Brevard, Inc.

Melbourne, Florida, 32935

Recruiting

Florida Cancer Specialists

N. Venice, Florida, 34275

Recruiting

Florida Cancer Specialists

Naples, Florida, 34102

Recruiting

Mid Florida Hematology and Oncology Center

Orange City, Florida, 32763

Recruiting

Cancer Care Centers of Brevard, Inc.

Palm Bay, Florida, 32909

Recruiting

Comprehensive Hematology Oncology

Palm Harbor, Florida, 34683

Recruiting

Florida Cancer Specialists

Port Charlotte, Florida, 33980

Recruiting

Cancer Care Centers of Brevard, Inc.

Rockledge, Florida, 32955

Recruiting

Florida Cancer Specialists

Sarasota, Florida, 34236

Recruiting

Comprehensive Hematology Oncology

St. Petersburg, Florida, 33701

Recruiting

Comprehensive Hematology Oncology

St. Petersburg, Florida, 33709

Recruiting

Comprehensive Hematology Oncology

Trinity, Florida, 34655

Recruiting

University Cancer & Blood Center, LLC

Athens, Georgia, 30607

Recruiting

Illinois Cancer Specialists

Arlington Heights, Illinois, 60005

Recruiting

Illinois CancerCare - Bloomington

Bloomington, Illinois, 61704

Recruiting

Illinois Cancer Specialists

Chicago, Illinois, 60631

Recruiting

Illinois CancerCare - Galesburg

Galesburg, Illinois, 61401

Recruiting

Hope and Healing Cancer Services

Hinsdale, Illinois, 60521

Recruiting

Hope and Healing Cancer Services

New Lenox, Illinois, 60451

Recruiting

Illinois Cancer Specialists

Niles, Illinois, 60714

Recruiting

Illinois CancerCare-Ottawa-Fox River Cancer Center

Ottawa, Illinois, 61350

Recruiting

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting

Illinois Cancer Care

Peoria, Illinois, 61615

Recruiting

Illinois CancerCare-Peru - Valley Regional Cancer Center

Peru, Illinois, 61354

Recruiting

Illinois CancerCare-Washington

Washington, Illinois, 61571

Recruiting

Franciscan Health

Indianapolis, Indiana, 46237

Recruiting

Franciscan Health Mooresville

Mooresville, Indiana, 46158

Recruiting

The Cancer & Hematology Centers

Big Rapids, Michigan, 49307

Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49503

Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49546

Recruiting

The Cancer & Hematology Centers

Holland, Michigan, 49424

Recruiting

The Cancer & Hematology Centers

Norton Shores, Michigan, 49444

Recruiting

Avera Cancer Institute- Marshall

Marshall, Minnesota, 56258

Recruiting

Cancer Partners of Nebraska

Lincoln, Nebraska, 68516

Recruiting

Renown Health Medical Oncology

Reno, Nevada, 89502

Recruiting

Renown Regional Medical Center

Reno, Nevada, 89502

Recruiting

NYOH Albany Cancer Center

Albany, New York, 12206

Recruiting

Hematology-Oncology Associates of Central New York, PC

Auburn, New York, 13021

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Babylon, New York, 11702

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Brooklyn, New York, 11210

Recruiting

Hematology-Oncology Associates of Central New York, PC

Camillus, New York, 13031

Recruiting

New York Oncology Hematology - Clifton Park Cancer Center

Clifton Park, New York, 12065

Recruiting

Hematology-Oncology Associates of Central New York, PC

East Syracuse, New York, 13057

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

New Hyde Park, New York, 11042

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

New York, New York, 10028

Recruiting

Hematology Oncology Associates of Rockland

Nyack, New York, 10960

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Patchogue, New York, 11772

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Port Jefferson Station, New York, 11776

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Riverhead, New York, 11901

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

Shirley, New York, 11967

Recruiting

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists

The Bronx, New York, 10469

Recruiting

Oncology Hematology Care - Eastgate

Cincinnati, Ohio, 45245

Recruiting

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106

Not Yet Recruiting

Oncology Hematology Care Clinical Trials, LLC

Fairfield, Ohio, 45014

Recruiting

Oncology Associates of Oregon, P.C.

Albany, Oregon, 97321

Recruiting

Kaiser Permanente Sunnyside Medical Center

Clackamas, Oregon, 97015

Recruiting

Oncology Associates of Oregon, P.C.

Corvallis, Oregon, 97330

Recruiting

Oncology Associates of Oregon, P.C.

Eugene, Oregon, 97401

Recruiting

Kaiser Permanente Westside Medical Center

Hillsboro, Oregon, 97124

Recruiting

Kaiser Permanente Interstate Medical Office Central

Portland, Oregon, 97227

Recruiting

Oncology Associates of Oregon, P.C.

Springfield, Oregon, 97477

Recruiting

Avera Cancer Institute- Aberdeen

Aberdeen, South Dakota, 57401

Recruiting

Avera Cancer Institute- Mitchell

Mitchell, South Dakota, 57301

Recruiting

Avera Cancer Institute- Pierre

Pierre, South Dakota, 57501

Recruiting

Avera Cancer Institute

Sioux Falls, South Dakota, 57105

Recruiting

AMG Oncology & Hematology -Yankton

Yankton, South Dakota, 57078

Recruiting

Henry-Joyce Cancer Clinic

Nashville, Tennessee, 37232

Recruiting

Texas Oncology - West Texas

Abilene, Texas, 79606

Recruiting

Texas Oncology - West Texas

Amarillo, Texas, 79124

Recruiting

Texas Oncology - Gulf Coast

Beaumont, Texas, 77702

Recruiting

Texas Oncology - Northeast Texas

Denison, Texas, 75020

Recruiting

Texas Oncology - Northeast Texas

Denton, Texas, 76201

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79902

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79915

Recruiting

Texas Oncology - West Texas

El Paso, Texas, 79938

Recruiting

Texas Oncology - Northeast Texas

Flower Mound, Texas, 75028

Recruiting

Oncology Consultants P.A.

Houston, Texas, 77008

Recruiting

Oncology Consultants P.A.

Houston, Texas, 77024

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77024

Recruiting

Oncology Consultants P.A.

Houston, Texas, 77030

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77054

Recruiting

Texas Oncology - Gulf Coast

Houston, Texas, 77070

Recruiting

Radnet/Houston Medical Imaging

Houston, Texas, 77098

Recruiting

Texas Oncology - Gulf Coast

Humble, Texas, 77338

Recruiting

US Oncology Investigational Products Center (IPC)

Irving, Texas, 75063

Recruiting

US Oncology Investigational Products Center

Irving, Texas, 75063

Recruiting

Texas Oncology - Northeast Texas

Longview, Texas, 75601

Recruiting

Texas Oncology - West Texas

Midland, Texas, 79701

Recruiting

Texas Oncology - West Texas

Odessa, Texas, 79761

Recruiting

Texas Oncology - Gulf Coast

Pearland, Texas, 77584

Recruiting

Texas Oncology - Gulf Coast

Sugar Land, Texas, 77479

Recruiting

Texas Oncology - Gulf Coast

The Woodlands, Texas, 77380

Recruiting

Texas Oncology - Northeast Texas

Tyler, Texas, 75702

Recruiting

Texas Oncology - West Texas

Wichita Falls, Texas, 76310

Recruiting

Virginia Cancer Specialists, PC

Arlington, Virginia, 22201

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Blacksburg, Virginia, 24060

Recruiting

Virginia Cancer Specialists, PC

Fairfax, Virginia, 22031

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Low Moor, Virginia, 24457

Recruiting

Virginia Cancer Specialists, PC

Manassas, Virginia, 20110

Recruiting

Virginia Cancer Institute

Mechanicsville, Virginia, 23116

Recruiting

Virginia Cancer Institute

Midlothian, Virginia, 23112

Recruiting

Virginia Cancer Institute

Petersburg, Virginia, 23805

Recruiting

Virginia Cancer Specialists, PC

Reston, Virginia, 20190

Recruiting

Virginia Cancer Institute

Richmond, Virginia, 23229

Recruiting

Virginia Cancer Institute

Richmond, Virginia, 23235

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Roanoke, Virginia, 24014

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Salem, Virginia, 24153

Recruiting

Virginia Cancer Specialists, PC

Woodbridge, Virginia, 22191

Recruiting

Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Wytheville, Virginia, 24382

Recruiting